Benzinga | Mar 10, 2021 04:36PM EST

Theratechnologies Reports 2 E-Posters To Be Presented At American Association For Cancer Research Apr. 10

Theratechnologies Inc. (Theratechnologies) (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that new positive pre-clinical data on TH1902, its lead peptide-drug conjugate (PDC) for the treatment of sortilin positive (SORT1+) solid tumors, will be presented in two e-posters during AACR Annual Meeting 2021.

Presentation Title: TH1902, a docetaxel peptide-drug conjugate, shows pre-clinical efficacy in several sortilin positive (SORT1+) cancers

Abstract Number: 1313

E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM

Presentation Title: Increasing potency of anticancer drugs through SORT1+ Technology: A new targeted approach for the treatment of ovarian and endometrial cancers

Abstract number: 1439

E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM

The abstracts are now available at aacr.org.